Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

445 Views

043. Clinical Trials: Thursday, 12:15 - 1:30 p.m.

Poster Session: Clinical Trials

(361) Evaluation of Resistance to Nirmatrelvir/ritonavir in Evaluation of Protease Inhibition for COVID-19 (EPIC) High-Risk and Standard-Risk Clinical Trials

Thursday, October 12, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Mary Lynn Baniecki, PhD

Head of Infectious Disease for Translational Medicine
Pfizer Inc
Cambridge, Massachusetts, United States

SG

Shunjie Guan, PhD in Statistics

Associate Director, Biomarker Statistics
Pfizer
Cambridge, Massachusetts, United States
ZW

Zhenyu Wang, Ph.D.

Pfizer
Cambridge, Massachusetts, United States
YC

Yan Chen, Ph. D

Director
Pfizer, Inc
Medford, Massachusetts, United States
WB

Weihang Bao, PhD

Pfizer Inc
New York, New York, United States
WH

Wen He, PhD

Pfizer
Groton, Connecticut, United States
ED

Elizabeth Dushin, PhD

Pfizer
Cambridge, Massachusetts, United States
CH

Craig Hyde, PhD

Sr. Director
Pfizer
Groton, Connecticut, United States
YZ

Yuao Zhu, PhD

Research Fellow
Pfizer, Inc.
Pearl River, New York, United States
RC

Rhonda D. Cardin, PhD

Executive Director
Pfizer, Inc.
Pearl River, New York, United States
Jennifer Hammond, PhD

Head of Antiviral Development
Pfizer Inc
Collegeville, PA, United States
SM

Sandeep Menon, PhD

Pfizer
Cambridge, Massachusetts, United States
CA

Charlotte Allerton, PhD

Pfizer
New York, New York, United States
HS

Holly Soares, PhD

Head Precision Medicine
Pfizer
Groton, Connecticut, United States